BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 36555398)

  • 1. New Therapeutics for Extracellular Vesicles: Delivering CRISPR for Cancer Treatment.
    Yan B; Liang Y
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapy.
    Ahmadi SE; Soleymani M; Shahriyary F; Amirzargar MR; Ofoghi M; Fattahi MD; Safa M
    Cancer Gene Ther; 2023 Jul; 30(7):936-954. PubMed ID: 36854897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosomes as Targeted Delivery Platform of CRISPR/Cas9 for Therapeutic Genome Editing.
    Duan L; Ouyang K; Wang J; Xu L; Xu X; Wen C; Xie Y; Liang Y; Xia J
    Chembiochem; 2021 Dec; 22(24):3360-3368. PubMed ID: 34418266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9: Principle, Applications, and Delivery through Extracellular Vesicles.
    Horodecka K; Düchler M
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered Cas9 extracellular vesicles as a novel gene editing tool.
    Osteikoetxea X; Silva A; Lázaro-Ibáñez E; Salmond N; Shatnyeva O; Stein J; Schick J; Wren S; Lindgren J; Firth M; Madsen A; Mayr LM; Overman R; Davies R; Dekker N
    J Extracell Vesicles; 2022 May; 11(5):e12225. PubMed ID: 35585651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extracellular vesicles as a potential delivery platform for CRISPR-Cas based therapy in epithelial ovarian cancer.
    Godbole N; Quinn A; Carrion F; Pelosi E; Salomon C
    Semin Cancer Biol; 2023 Nov; 96():64-81. PubMed ID: 37820858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-derived extracellular vesicles for CRISPR/Cas9 delivery: engineering strategies for cargo packaging and loading.
    Liang Y; Iqbal Z; Wang J; Xu L; Xu X; Ouyang K; Zhang H; Lu J; Duan L; Xia J
    Biomater Sci; 2022 Jul; 10(15):4095-4106. PubMed ID: 35766814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomaterial-assisted targeted and controlled delivery of CRISPR/Cas9 for precise gene editing.
    Iqbal Z; Rehman K; Xia J; Shabbir M; Zaman M; Liang Y; Duan L
    Biomater Sci; 2023 May; 11(11):3762-3783. PubMed ID: 37102700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tropism-facilitated delivery of CRISPR/Cas9 system with chimeric antigen receptor-extracellular vesicles against B-cell malignancies.
    Xu Q; Zhang Z; Zhao L; Qin Y; Cai H; Geng Z; Zhu X; Zhang W; Zhang Y; Tan J; Wang J; Zhou J
    J Control Release; 2020 Oct; 326():455-467. PubMed ID: 32711027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
    Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
    Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and prospective strategies for advancing the targeted delivery of CRISPR/Cas system via extracellular vesicles.
    Huang X; Li A; Xu P; Yu Y; Li S; Hu L; Feng S
    J Nanobiotechnology; 2023 Jun; 21(1):184. PubMed ID: 37291577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene Editing by Extracellular Vesicles.
    Kostyushev D; Kostyusheva A; Brezgin S; Smirnov V; Volchkova E; Lukashev A; Chulanov V
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33028045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering extracellular vesicles to deliver CRISPR ribonucleoprotein for gene editing.
    Whitley JA; Cai H
    J Extracell Vesicles; 2023 Sep; 12(9):e12343. PubMed ID: 37723839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Genome Editing and In Vivo Delivery.
    Ramirez-Phillips AC; Liu D
    AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
    Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
    Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research Progress on Nanoparticles-Based CRISPR/Cas9 System for Targeted Therapy of Tumors.
    Nie D; Guo T; Yue M; Li W; Zong X; Zhu Y; Huang J; Lin M
    Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revolutionizing Lung Cancer Treatment: Innovative CRISPR-Cas9 Delivery Strategies.
    Singh D
    AAPS PharmSciTech; 2024 Jun; 25(5):129. PubMed ID: 38844700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress of delivery methods for CRISPR-Cas9.
    Yang W; Yan J; Zhuang P; Ding T; Chen Y; Zhang Y; Zhang H; Cui W
    Expert Opin Drug Deliv; 2022 Aug; 19(8):913-926. PubMed ID: 35818792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.